key: cord-0876400-xkoilncd
authors: Sohag, Abdullah Al Mamun; Hannan, Md Abdul; Rahman, Sadaqur; Hossain, Motaher; Hasan, Mahmudul; Khan, Md Kawsar; Khatun, Amena; Dash, Raju; Uddin, Md Jamal
title: Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
date: 2020-07-06
journal: Drug Dev Res
DOI: 10.1002/ddr.21709
sha: 75f451d35a7d36442711d53d26149470a111ad11
doc_id: 876400
cord_uid: xkoilncd

Coronavirus disease‐19 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID‐19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines, which may require considerable time. In this uncertainty, repurposing the existing antiviral drugs could be the best strategy to speed up the discovery of effective therapeutics against SARS‐CoV‐2. Moreover, drug repurposing may leave some vital information on druggable targets that could be capitalized in target‐based drug discovery. Information on possible drug targets and the progress on therapeutic and vaccine development also needs to be updated. In this review, we revisited the druggable targets that may hold promise in the development of the anti‐SARS‐CoV‐2 agent. Progresses on the development of potential therapeutics and vaccines that are under the preclinical studies and clinical trials have been highlighted. We anticipate that this review will provide valuable information that would help to accelerate the development of therapeutics and vaccines against SARS‐CoV‐2 infection.

5. NSP 3, 4, and 6 are responsible for anchoring the coronavirus replication and transcription complex through recruitment of intracellular Endoplasmic Reticulum (ER) membrane to form doublemembrane vesicles (Fehr & Perlman, 2015; Sola et al., 2015; Stertz et al., 2007) .

6. Viral nucleocapsids are assembled with genomic RNA and N protein in the cytoplasm, followed by budding into the lumen of the ERGIC (Endoplasmic Reticulum-Golgi Intermediate Compartment; Sola et al., 2015; Stertz et al., 2007) .

7. The virions are then released from the cell through exocytosis (Sola et al., 2015; Stertz et al., 2007) .

To find a potential therapy for SARS-CoV-2, a concrete understanding of potential drug targets is essential. Herein, we revisited a comprehensive list of SARS-CoV-2-directed targets (M pro , PLpro, RdRp, spike protein, helicase, envelop protein) and host-directed targets (ACE2, TMPRSS2, and immune system) that might hold promise for the development of potential therapy against SARS-CoV-2 infections Two large overlapping replicase polyproteins (pp1a and pp1ab), encoded by two linked ribosomal frameshift, are hydrolyzed by an extensive proteolytic action of viral proteases (Fehr & Perlman, 2015; Graham, Sparks, Eckerle, Sims, & Denison, 2008; Pillaiyar, Manickam, Namasivayam, Hayashi, & Jung, 2016) . One of the crucial viral proteases is the M pro , also known as 3C-like proteinase or NSP5, which is a homodimeric cysteine protease belonging to the coronavirus polyprotein group (Fan et al., 2004) . Automatic cleavage of polyproteins leads to the generation of M pro , which cleaves the large polyprotein 1ab at 11 cleavage sites to generate NSPs. The identification of cleaving sequence at most sites is Leu-Gln#(Ser, Ala, Gly) to release NSP4-NSP16 (Pillaiyar et al., 2016; Yang et al., 2005; Zhang, Penninger, Li, Zhong, & Slutsky, 2020) . M pro directly mediates the maturation of NSPs, which is critical for the initiation of the SARS-CoV-2 replication cycle and could, therefore, be a potential druggable target . For instance, pyridone-containing α-ketoamides inhibited the M pro activity showing early promise for the development of anti-viral drugs . Moreover, more than a hundred PDB structures of SARS-CoV-2 M pro have already been deposited at the RCSB database (https://www.rcsb.org/) and more are being added regularly. Here, most of the structures were elucidated by Cryo-electron microscopy, NMR or X-ray crystallography, or even the high-throughput network-based inhibitor screening or direct ligand-based study Vuong et al., 2020) . While ligandbased inhibitors screening leads to the determination of complexed crystal structure of SARS-CoV-2 M pro , this approach aids in the structure-assisted drug design and high-throughput screening for potential F I G U R E 1 (a) A schematic diagram of the SARS-CoV-2 (modified from Du et al., 2009 ). S, Spike protein; E, envelope protein; singlestranded positive-sense viral RNA, and M, membrane protein are depicted. (b) A schematic diagram of the SARS-CoV-2 life cycle in a host cell (modified from Du et al., 2009) . (1) Virus entry into the host cell via ACE2 or endocytosis, (2) Release of RNA from endosome, (3) Proteolytic cleavage of polyprotein, (4) synthesis of genomic and subgenomic RNA, (5) structural protein synthesis and maturation, and (6) Assembly of viral particles and mature viral particle. 3CLpro, chymotrypsin-like protease; ACE2, Angiotensin-converting enzyme 2; E, Envelope protein; M, membrane protein; N, nucleocapsid; PLpro, papain-like protease; S, Spike protein; TMPRSS2, Transmembrane protease, serine 2 inhibitors . The inhibitors targeting SARS-CoV-2 M pro are virus-specific and, therefore, will not interfere with host cell proteases (Bzówka et al., 2020) .

Proteolytic enzymes play an essential role in viral replication, and hence could be the target of choice for the development of effective therapy against viral infections. PLpro, also termed as NSP 3, had been extensively studied for coronaviruses (Báez-Santos et al., 2015; Lei et al., 2014; Ratia et al., 2006) and the efficacy of PLpro inhibitors such as chloroquine and formoterol have been investigated recently for the treatment of COVID-19 (Rimanshee, Amit, Vishal, & Mukesh, 2020; Wu et al., 2020) . PLpro cleaves the N-terminal part of the polyproteins producing mature NSP1, NSP2, and NSP3, a process that is crucial for viral replication. The cleavage specificity of PLpro corresponds to the pattern (R/K)L(R/K)GG#X. Moreover, the enzyme acts as deubiquitinase that removes (poly) ubiquitin units from proteins tagged with them (Barretto et al., 2005; Lindner et al., 2005) .

The deubiquitinase activity of PLpro interferes nuclear import of interferon-regulatory factor 3 and the phosphorylation, thereby preventing the production of type-I interferons, such as IFN-α and IFN-β by the infected host cell and also helps in peptide substrate recognition (Barretto et al., 2005; Clementz et al., 2010; Devaraj et al., 2007; Frieman, Ratia, Johnston, Mesecar, & Baric, 2009; Ratia et al., 2006) . Additionally, PLpro clears ubiquitin and interferon-sensitive gene 15 from host-cell proteins, a mechanism that aids coronaviruses to evade host innate immune responses. Finally, the PLpro has been reported to interfere with the nuclear factor κB pathway, which further assists SARS-CoV to counteract the innate immune response of the infected cells (Clementz et al., 2010) . Therefore, pharmacological targeting of PLpro by developing PLpro inhibitors might constitute a potential therapeutic strategy that would be advantageous in not only preventing viral replication but also ensuring the normal regulation of signal networks in the infected cells.

F I G U R E 2 A schematic diagram indicating the potential drug targets and drugs on viral replication processes. (1) ACE2 and spike complex inhibitors: Azithromycin and Chloroquine, interrupt in ACE2 and S protein complex formation; (2) TMPRSS2 inhibitor: Camostat Mesylate blocks cleavage and activation of the S protein; (3) Targeting endosomes: chloroquine and its derivatives increase pH and inhibit viral RNA release from endosomes; (4) Targeting proteases: ASC09F, Oseltamivir, Ritonavir, Oseltamivir, Oseltamivir, Lopinavir inhibit proteases thereby inhibit viral replication; (5) Targeting RdRp: Favipiravir, Remdesivir, and Ribavirin block RdRp and cause premature termination of RNA synthesis; (6) Targeting Spike: Monoclonal antibody, Arbidol, and convalescent plasma block spike protein which results into binding interruption with ACE2; (7) Targeting host immune system: activated host immune system can block virus propagation as well as recover body from the adverse effects posed by viruses RNA dependent RNA polymerase RdRp, also termed as NSP 12, is a pivotal enzyme of RNA viruses, including coronavirus, that catalyzes the replication of RNA from an RNA template, probably with the assistance of NSP7 and NSP8 as cofactors (Guo, Huang, Lin, & Lv, 2020; Kirchdoerfer & Ward, 2019; Subissi et al., 2014; Venkataraman, Prasad, & Selvarajan, 2018) . A protein complex consisting of NSP 7, NSP 8, and NSP 12 of SARS-CoV-2 is related to that of SARS-CoV with a root-mean-square deviation value of 0.82 for 1,078 Cɑ atoms . RdRp protein of SARS-CoV-2 and SARS-CoV share 96% amino acid sequence identity and 82% sequence identity at their genomic RNA level (Morse, Lalonde, Xu, & Liu, 2020) . The RdRp of SARS-CoV-2 contains a large and deep groove as an active site for the polymerization of RNA. Residues that show variations between the SARS-CoV-2 and SARS-CoV RdRps are mostly distal to this active site. This high sequence conservation and structural homogeneity of RdRp in coronaviruses suggest that nucleotide analogs developed for the SARS-CoV RdRp are likely to be effective against the SARS-CoV-2 RdRp (Morse et al., 2020) . Previously published literature provides convincing evidence that RdRp could be a druggable target for the development of potent therapy against SARS-CoV-2 infection (Kandeel, Ibrahim, Fayez, & Al-Nazawi, 2020; Lung et al., 2020) , which includes nucleotide analog targeting RdRp (Deval, Jin, Chuang, & Kao, 2017; Stephen & Lin, 2018; Tchesnokov, Feng, Porter, & Götte, 2019) . Remdesivir (GS-5734), a prodrug and adenosine analog, can be incorporated into nascent viral RNA, and subsequently inhibit the RdRp (Siegel et al., 2017) . Furthermore, Remdesivir showed high considerable efficacy in controlling SARS-CoV-2 infection in a recent in vitro study . β-D-N4-hydroxycytidine, a ribonucleoside analog, also inhibits SARS-CoV-2 replication as evidenced by reducing viral genomic RNA .

Helicase SARS-CoV helicase (NSP13) is one of the 16 NSPs generated after the proteolytic cleavage of two large polyproteins (pp1a and pp1ab). This helicase, being one of the components of the replicase-transcriptase complex, plays significant roles in the life cycle of SARS-CoV (Marra et al., 2003; Subissi et al., 2014) , which constitutes the basis of targeting this enzyme for the development of potential antiviral agent. Helicases are motor proteins that unwind double-stranded nucleic acids into two single-strands during replication (Adedeji et al., 2014; Shum & Tanner, 2008) . Moreover, NSP13 N-terminus carries 26 cysteines where 14 positions are highly conserved and assumed to possess a binuclear Zn 2+binding cluster (Seybert et al., 2005) . Importantly, an antiviral compound Bananin, which is an adamantane derivative, has been reported to inhibit helicase activities, thereby preventing the replication of SARS-CoV (; Tanner et al., 2003) and can also be evaluated against SARS-CoV-2.

The spike protein (S), giving a crown-like appearance to virion surface, render diverse molecular actions that usually mediates the coronavirus entry into the specific host (Belouzard, Chu, & Whittaker, 2009 ). The spike protein of SARS-CoV and SARS-CoV-2 shares 76% amino acid identity; however, SARS-CoV-2 S protein binds 10 times more strongly than SARS-CoV S protein to their common host cell receptor (Du et al., 2009; Hoffmann et al., 2020; Li, 2016; Tortorici et al., 2019; Wrapp et al., 2020) . Heavily glycosylated, the spike protein possesses a large ectodomain, a single-pass transmembrane anchor, and a short intracellular tail (Li, 2016) . The ectodomain consists of a receptor-binding subunit (S1) and a membrane-fusion subunit (S2; Broer, Boson, Spaan, Cosset, & Corver, 2006; Li, 2016) .

During virus entry, the S1 subunit recognizes and interacts to host receptors, and further conformational changes in the S2 subunit assist the fusion between the viral envelope protein and the host cell membrane (Du et al., 2009; Li, 2016; Tortorici et al., 2019) . S1 subunit has two major domains: the N-terminal domain (NTD) and the C-terminal domain (CTD). Depending on the coronavirus type, either CTD or NTD can function as the RBD and bind with diverse proteins and sugars (Li, 2016) . Notably, SARS-CoV and MERS-CoV utilize CTD to bind their receptors (Kubo, Yamada, & Taguchi, 1994; Li et al., 2005; Ou et al., 2020; N. Wang et al., 2013) . Then, the proteases found in the cellular environment cause the cleavage of S proteins, which ensures viral fusion. SARS-CoV-2 possesses a furin cleavage site between S1 and S2 subunit that permits efficient cleavage by proteases, including furin that determines viral infectivity and host range (Andersen et al., 2020; Coutard et al., 2020; Ou et al., 2020; Walls et al., 2020) . The S protein of the SARS-CoV-2 contains a furin-like cleavage site, which is absent in other coronaviruses of the same clade (Coutard et al., 2020) . The S protein also activates the immune response of the host cell toward coronaviruses (Dosch, Mahajan, & Collins, 2009; Walls et al., 2020) .

Since the S protein of coronaviruses is reported for their vital associations with initial receptor binding and other critical membrane fusion steps, they could be putative targets for blocking the infection. Prior studies revealed that peptide inhibitors to SARS-CoV-2 S protein provide promising avenues for SARS-CoV-2 treatment by blocking the S protein interaction with ACE2 and thus efficiently preclude the virus entry into human cells. Moreover, these inhibitors can be used as inhaled therapeutics, preventing the virus activation in the lungs (Ou et al., 2020; Walls et al., 2020) .

Recently, Wan et al. (2020) and Tai et al. (2020) sequenced and characterized RBD of SARS-CoV-2, including its receptor-binding motif (RBM) that directly associates with ACE2. They also identified some important amino acid residues in SARS-CoV-2 RBM (especially Gln493), which facilitates the interactions with human ACE2 and reveals the high capacity of SARS-Cov-2 human infection. Moreover, other crucial amino acid residues in SARS-CoV-2 RBM, particularly Asn501, contributed SARS-CoV-2, gaining some ability for human-tohuman transmission (Tai et al., 2020; Wan et al., 2020) . It was also found that five important amino acids of RBD are conserved in Pangolin-CoV and SARS-CoV-2 (Zhang, Lin, et al., 2020) . These findings would give valuable information for finding antigens with improved sensitivity for SARS-CoV-2 serological detection and vaccine development.

Envelope protein E protein of coronavirus is a short polypeptide integral membrane protein that has been involved with different steps of the life cycle of the virus, such as assembly, budding, envelope formation, and pathogenesis (Masters, 2006) . It has been reported that the absence or inactivation of E protein could impact either virion morphology or tropism (Khattari et al., 2006; Pervushin et al., 2009 ). E proteins of coronaviruses have shown cation-selective ion channel activity and thus have membrane permeabilizing property (Wilson, McKinlay, Gage, & Ewart, 2004) .

SARS-CoVs lacking E protein show lower viral titer, immature, and inefficient progenies (Kuo, Hurst, & Masters, 2007) , thereby recommending E protein a suitable drug target to prevent viral replication and infection.

3.2 | Host cell target 3.2.1 | Angiotensin-converting enzyme 2 ACE2 is a type I membrane protein, which is expressed in the heart, lungs, kidneys, and intestine. An N-terminal peptidase domain (PD) and a C terminal Collectrin-like domain (CLD) are usually found in a fulllength ACE2 (Donoghue et al., 2000; H. Zhang et al., 2001) . A recent report demonstrated that the ectodomain of the SARS-CoV-2S protein interacts with the PD of ACE2 (Wrapp et al., 2020) . Like SARS-CoV, the SARS-CoV-2 virus exploits the ACE2 receptor to gain entry into host cells. Human cell-derived proteases cleave SARS-CoV-2 S protein into S1 and S2, where S1 initially interacts its receptor molecule ACE2, and the other fragment, S2, further leads to the membrane fusion after the cleavage by a human cell surface serine protease (TMPRSS2) (Hoffmann et al., 2020) . These findings provide valuable insights into the molecular basis for coronavirus recognition and infection. The S protein of SARS-CoV-2 is approximately 10-to 20-fold more likely to bind to human ACE2 protein the S protein of SARS-CoV (Wrapp et al., 2020) . This increase in affinity might have facilitated a more favorable person-toperson transmission of the SARS-CoV-2 infection than the SARS-CoV (Hoffmann et al., 2020) . ACE2 can thus act as a unique adhesion protein molecule for SARS-CoV-2 infection and be a promising drug target for the prevention of SARS-CoV-2 infection. Disrupting the interaction between spike protein and ACE2 might, therefore, be a possible way of developing a drug against SARS-CoV-2. A Phase 1 and Phase 2 clinical trial of human recombinant soluble ACE2 (hrsACE2), a 23-mer peptide fragment, was carried out recently and suggested to use for the treatment of COVID-19 (Khan et al., 2017; Zhang, Penninger, et al., 2020) .

SARS-CoV-2 infected Vero-E6 lines were incubated with hrsACE2 and found that hrsACE2 can preclude the early entrance of SARS-CoV-2 infections in host cells perhaps by binding with RBD of S protein (Monteil et al., 2020).

Although the ACE2 is available in the vascular endothelial cells of all organs, the lungs are more susceptible to SARS-CoV infection (Hamming et al., 2004) . This phenomenon strengthens the possibility of other factors associated with the actual pathogenesis of SARS-CoV-2. One such factor which accounts for the viral entry into host cells is TMPRSS2, a well-known human alveolar and airway protease (Shulla et al., 2011) . TMPRSS11a, a TMPRSS2 related protein, has been found to cleave SARS-CoV S protein and to moderately accelerate viral infections (Kam et al., 2009 ). TMPRSS2 probably facilitates viral pathogenesis and transmission in two ways: First, TMPRSS2 might activate SARS-CoV S protein for virus-cell and cell-cell fusion.

Second, TMPRSS2 might protect viral recognition by different neutralizing antibodies of the host (Glowacka et al., 2011) . Evidence suggests that the entry of SARS-CoV-2 into host cells requires both ACE2 and TMPRSS2 (Hoffmann et al., 2020) , thereby suggesting that TMPRSS2 might be a potential drug target. Matsuyama et al. (2020) showed that a TMPRSS2-expressing in VeroE6 cell line is highly susceptible to SARS-CoV-2 infection displaying the critical role of TMPRSS2 in the pathogenesis of this viral disease. Previously, Bromhexine hydrochloride, an FDA approved component in mucolytic cough suppressants, showed specific inhibition on TMPRSS2 with no adverse effect in prostate cancer patients and reduction of the progression of metastasis (Lucas et al., 2014) . Bromhexine hydrochloride might be repurposed as a TMPRSS2 inhibitor for preventing SARS-CoV-2 infection as well (Hoffmann et al., 2020) .

Cytokine storm SARS-CoV-2 causes imbalanced and exuberant immune responses termed as cytokine release syndrome or cytokine storm, which triggers lung impairment and reduces the survival of the infected patients (Pedersen & Ho, 2020; Tisoncik et al., 2012) . The inflammatory cytokines are usually produced by different macrophages, which are associated with cytokine storm (Luo et al., 2020; Pedersen & Ho, 2020) . SARS-CoV-2 significantly increases levels of proinflammatory cytokines such as IL-6, IL-10, and TNFα in infected patients (Channappanavar et al., 2016; Diao et al., 2020; Nikolich-Zugich et al., 2020) . Furthermore, SARS-CoV-2 induced activation of a cluster of differentiation four positive (CD4 + ) T cells stimulate the generation of T helper cells and secrete interleukin (IL)-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF triggers monocytes to further release of IL-6 and other factors, resulting in the generation of a cytokine storm. This cytokine storm results in acute respiratory distress syndrome, multiple organ failure, and even death (Chen, Zhang, et al., 2020a; Zhou et al., 2020) . Targeted immunomodulation to decrease cytokine storm might be a feasible option to reduce pulmonary inflammation and mortality. Since only antiviral candidates may not be enough to combat such cytokine storm or complications in the respiratory tract, identifying effective targets for immune therapeutics along with antiviral agents could be a potential strategy. Preliminary results from a study suggest that Hydroxychloroquine might have anti-cytokine storm properties (Yao et al., 2020) . Additionally, Lenziluman has been reported to be protective against cytokine storm and neurotoxicity in mouse models.

Furthermore, Lenzilumab, an anti-GM-CSF monoclonal antibody, can be considered as a viable therapeutic option as COVID-19 patients (Sterner et al., 2019) .

The innate immune response itself, without the association of CD8 + T cells and antibodies, is capable of controlling SARS-CoV (Frieman, Heise, & Baric, 2008) . NK cells are the part of innate lymphocyte subsets that mediate anti-tumor and antiviral responses, and therefore have the potential for clinical use (Abel, Yang, Thakar, & Malarkannan, 2018) . Previous studies showed that NK cells showed significant roles in mitigating of SARS-CoV  National Research Project for SARS (NSPS), 2004). Recent epidemiological studies showed that SARS-CoV-2 infection in children is less frequent and lethal compared to that of adults, which might be due to the increased lymphocyte count, especially NK cells and trained immunity in children (Cristiani et al., 2020) . Therefore, the approaches focused on valorizing the innate antiviral immune responses are a possible way to find a remedy against SARS-CoV-2. Arabinoxylan treatment resulted in the upregulation of NK cells against neuroblastoma in vitro and in vivo studies (Pérez-Martínez et al., 2015) . Arabinoxylan, therefore, possesses potentiality for the treatment of COVID-19 patients; however, clinical trials are needed to determine its effectivity.

Autophagy is a natural mechanism of a cell which ensures the maintenance of cellular homeostasis by lysosomal catabolic action, leading the degradation and recycling of intracellular endogenous (macromolecules, abnormal proteins, and damaged organelles) and exogenous (viruses and bacteria) particles (Galluzzi et al., 2017; Levine & Klionsky, 2004) . Some viruses have developed strategies to escape autophagic degradation and use host autophagy machinery for their self-replication (Dong, Dong, & Levine, 2013) . The significance of the autophagy process and its therapeutic development for SARS-CoV, MERS-CoV, and SARS-CoV-2 are reviewed by . A recent study showed that MERS-CoV halts the fusion of autophagosomes and lysosomes, whereas inhibitors like S-phase kinase-associated protein 2 induced autophagy, which leads to the reduction of the replication of MERS-CoV (Gassen et al., 2019) . Thus, it seems that a considerable relationship exists between the autophagy machinery and coronavirus infections; therefore, these relationships need to be elucidated in SARS-CoV-2 to understand disease prognosis and also to enhance autophagocytosis as a possible treatment corridor.

Many potential therapeutics are currently in different stages of clinical trials, to find out an effective treatment for COVID-19, including drugs that have already proven effective for other viral diseases such as human immunodeficiency virus (HIV) and malaria. Drug repurposing could be a rational strategy to develop urgent therapeutics. More than one drug and treatment strategy might prove its worth, and different strategies might work effectively at different infection stages and risk groups. The big challenge will be conducting clinical trials on an urgent basis, determining the effectiveness of different drugs alone or in combination. However, the scientists should take caution to avoid mistakes that occurred during the West African Ebola epidemic, in which haphazard experiments flourished and randomized clinical trials were framed up so late, resulting in little patients in the trial. Besides, developing new drugs or testing procedures may take several years to develop. That is why the World Health Organization (WHO) and other organizations are emphasizing the repurposing therapeutic candidates that have already been approved for other diseases. Researchers are studying antiviral drugs that have performed well in animal studies against SARS-CoV and MERS-CoV as well to determine their effectivity against SARS-CoV-2. Here, we reviewed some of the potential therapeutics and antivirals, which are under preclinical study and clinical trials. This review would help researchers to get quick and collective information regarding potential drugs.

As virus entry is a crucial step for the pathogenesis of the COVID-19, we provide a comprehensive list of repurposed drugs/chemicals that have been reported to block viral entry via different mechanisms (Table 1) . Monotherapy or combined therapy of these drugs are in preclinical, Phase 1, Phase 2, or Phase 3 clinical trials. Hoffmann et al. (2020) showed that Camostat mesylate interferes with TMPRSS2-mediated viral entry, thus reduces the severity of the COVID-19 disease. Similarly, Arbidol, an antiviral that inhibits the hemagglutinin of the influenza virus and blocks the entry into the cell, is recommended to use against influenza viruses and arboviruses (Kadam & Wilson, 2017; Wang et al., 2004 ). An open, prospective/retrospective, randomized controlled cohort study is underway at Tongji Hospital, China, to study the safety and efficacy of Arbidol Hydrochloride and Arbidol Hydrochloride combined with interferon atomization in humans (Table 1) . In this study, the interventional subjects will be given a standard supportive therapy with Arbidol Hydrochloride (0.2 g, three times a day) or Arbidol Hydrochloride combined with Interferon (PegIFN-α-2b) atomization (45 g) (NCT04254874). Trials with Arbidol Hydrochloride, along with other drugs, are also undergoing at Ruijin Hospital, China, and Tongji Hospital, China (NCT04260594, NCT04255017). Moreover, a recent study has demonstrated that a fusion protein made of rhACE2 and an Fc (Fragment crystalization) region of the human immunoglobulin IgG1 shows highaffinity binding to the receptor-binding domain of SARS-CoV-2 and potently neutralized SARS-CoV-2 in vitro, which provides a basis for further drug development Monteil et al., 2020) . This fusion protein can be considered for further studies in animals and 

The replication cycle of coronavirus or the virus-infected host cells possesses several virus-specific processes or protein molecules that could be targeted for effective antiviral drug design. An effective antiviral agent might halt the viral progression in the infected cell without being allergic or toxic to surrounding noninfected cells (Zhu, Meng, Wang, & Wang, 2015) .

We have already discussed above the role of endosomal/lysosomal acidification and the role of their acidic pH-dependent proteases in the virus life cycle . The inhibition of this pathway might be a potential therapeutic strategy. Several therapeutics such as Chloroquine (CQ), a well-studied lysosomotropic antimalarial drug, and its derivatives hydroxychloroquine and colchicine would be an option for blocking this target. CQ effectively blocks viral progression by raising endosomal pH needed for membrane fusion between the host cell and viral candidates and releasing RNA from endosomes (Savarino, Boelaert, Cassone, Majori, & Cauda, 2003) .

Although CQ and hydroxychloroquine were found to be effective against SARS-CoV-2 (Gautret et al., 2020; 

Proteases have a crucial role in many signaling pathways and represent promising drug targets fora wide range of diseases, including viral diseases. A few protease blockers are currently under Phase 1, Phase 2, or Phase 3 clinical trials as potential drugs for treating COVID-19 (Tables 1   and 2 ). ASC09/Ritonavir, Lopinavir/Ritonavir, ASC09F + Oseltamivir, and Ritonavir + Oseltamivir are some protease inhibitor drug candidates that inhibit 3CLpro and prevent subsequent progression of replication (Table 1) (Table 3) . A recent case report claimed that a 54-year-old patient administered with lopinavir/ritonavir showed a significant reduction of viral loads with no or little coronavirus titers (Lim et al., 2020) . A recent clinical trial (ChiCTR2000029308), however, showed that lopinavir-ritonavir treatment caused no benefit to hospitalized patients with severe COVID-19 compared to standard care . Treatment with lopinavir-ritonavir was not associated with time to clinical improvement, mortality at 28 days, detectable viral RNA, and gastrointestinal adverse events compared with the standard-care group . These contradictory yet promising findings highlight the importance of conducting clinical trials before using a drug as a therapeutic candidate. (Brown, 2009; Velkov et al., 2014) . Favipiravir (T-705) is a broad-spectrum prodrug that is metabolized into an active ribofuranosyl triphosphate derivative that selectively inhibits the viral RdRp polymerase activity (Velkov et al., 2014) . Favipiravir was shown to inhibit the replication of the respiratory syncytial virus and also been proven effective against influenza in Japan (Delang, Abdelnabi, & Neyts, 2018; Furuta, Komeno, & Nakamura, 2017) , which indicates that it might be effective against SARS-CoV-2. A multicenter, randomized, and controlled clinical trial study with 150 participants is underway with

Favipiravir combined with Tocilizumab for the treatment of COVID-19 at Peking University First Hospital (Table 3) (Cai et al., 2020) . Remdesivir, an adenosine nucleoside analog prodrug and developed by Gilead Sciences (Foster City, CA) against the Ebola virus, incorporates into nascent viral RNA chains resulting in the premature termination of RNA synthesis . Monotherapy and combination therapy of Remdesivir with CQ or Interferon-beta (IFN-β) halted SARS-CoV-2 replication and treated patients were clinically recuperated (Khalili, Zhu, Mak, Yan, & Zhu, 2020) . It could be used as a broad-spectrum antiviral therapeutic agent that has already been reported against a wide range of DNA and RNA viruses such as paramyxovirus, Influenza A and B, Hepatitis C, respiratory syncytial virus, parainfluenza, and HIV (Elfiky, 2020; Khalili et al., 2020; Tam, Lau, & Hong, 2001; Tan et al., 2004) . for the treatment of SARS-CoV-2 as alone or in combination with other drugs (Table 3 ; Khalili et al., 2020) .

Inflammation is an obvious outcome of SARS-CoV-2; however, no effective therapeutics targeting the inflammatory responses for SARS-CoV-2 has been approved to date. Fu, Cheng, and Wu (2020) reviewed the potential mechanism of Fc receptor (FcR) blockers such as intravenous immunoglobulin, anti-Fc specific antibodies, small molecules, and so on, which might be a therapeutic tool for reducing SARS-CoV-2 induced pulmonary inflammation. Moreover, anti-inflammatory drugs or corticosteroids might also effectively alleviate early proinflammatory response to reduce SARS-CoV-2-induced inflammatory responses by blocking FcR activation. Besides, the administration of intravenous immunoglobulin against FcR could be effective for an urgent remedy against pulmonary inflammation associated with severe lung injury as it can effectively block FcR activation. These approaches may also be applied with corticosteroids or systemic antiinflammatory drugs (Shang, Zhao, Hu, Du, & Cao, 2020) , which needs further clinical trials to study the effectiveness against SARS-CoV-2 infection (Russell, Millar, & Baillie, 2020) .

Another potential option for reducing inflammation is Siltuximab, a chimeric monoclonal antibody (mAb) that binds to and halts the effect of IL-6 (Sarosiek, Shah, & Munshi, 2016; .

Recently, a study in COVID-19 patients showed that intravenous administration of Siltuximab improved clinical conditions of 33% patients, stabilized or demonstrated no clinically relevant changes in 43% of patients, whereas condition deteriorated in 24% patients (Gritti et al., 2020) . These results exhibit the potential role of Siltuximab in treating patients with SARS-CoV-2 infection (Gritti et al., 2020) . Furthermore, an observational case-control study with 50 COVID-19 patients with serious respiratory complications is ongoing in Italy to determine the effectivity of Siltuximab (NCT04322188). Table 4 .

A vaccine is an ultimate hope to prevent and reduce the spread of COVID-19. A vaccine can be either prophylactic, which prevents future infection or therapeutic, which is used to treat diseases such as cancer or infectious diseases (Frazer, 2014; Guo et al., 2013) . The whole pathogen (either killed or live-attenuated), or parts of the pathogen, such as nucleic acid, proteins, or peptides, can be used as vaccines (Haque, Shah, Paul, & Barua, 2020; Shah & Md Kawsar, 2015) . Whole virus vaccines have been widely studied and showed protection against the influenza virus (Fiore, Bridges, & Cox, 2009) , the human papillomavirus, and the chickenpox virus (Liesegang, 2009 ); whereas, subunit and peptidebased vaccines have shown immunity in vitro (Khan, Hossain, Rakib-Uz-Zaman, & Morshed, 2014) and animal studies (Islam, Clemens, & Qadri, 2018) . There were efforts to develop vaccines against SARS-CoV and MERS-CoV, which were tested in animal models (Gao et al., 2003; Kim et al., 2014) . However, there is no benign and operational vaccine available against SARS-CoV until now. Development of vaccines against SARS-CoV after the SARS outbreak in 2002-2004 was attempted (Greenough et al., 2005; Roberts et al., 2006; Tripp et al., 2005) ; however, the efforts did not result in finding any effective vaccines until now. During MERS prevalence, it was believed that SARS-CoV would provide a foundation and a template for developing vaccines against MERS-CoV infection (Jiang, Lu, & Du, 2013) . However, only one MERS-CoV DNA vaccine has so far completed a Phase 1 clinical trial (Yong, Ong, Yeap, Ho, & Tan, 2019) . Several more viral vectored-MERS-CoV vaccines are in progress (Yong et al., 2019) which were reviewed by Zumla, Chan, Azhar, Hui, and Yuen (2016) . harmless and ready to be tested (NCT04283461). However, no vaccine has completed any clinical trial yet, and no vaccines are available to prevent SARS-CoV-2 infection (Amanat & Krammer, 2020; Chen, Zhang, et al., 2020b) .

In the passive antibody therapy approach, the antibodies from the blood plasma or serum (convalescent plasma or sera) of people who have recuperated from SARS-CoV-2 infection are used to enhance the immunity of newly infected patients and those at risk of the disease, such as frontline caregivers or essential service providers. These serum antibodies can bind to and neutralize SARS-CoV-2 (Casadevall & Pirofski, 2020 ). The precise timing of collecting blood from the recovered patient is crucial to boost the immunity of the patients (Casadevall & Pirofski, 2020) . Such approaches of using convalescent sera or plasma were used effectively in the past during mumps and measles epidemics (Casadevall & Pirofski, 2020) . This approach has already been applied in China, where five SARS-CoV-2 infected, severely ill patients with acute respiratory distress syndrome were treated with convalescent plasma transfusion from five different recovered patients (Chen, Zhang, et al., 2020a; Teixeira da Silva, 2020) .

This initiative showed promising results and improved the clinical condition of the treated patients . However, the limited number of participants in this study precludes a definitive statement about the potential effectiveness of administering convalescent plasma. It emphasizes the need for an evaluation in clinical trials with a larger sample size and proper randomized study design . Recently, convalescent plasma therapy has started to treat 245 COVID-19 patients (Casadevall & Pirofski, 2020) ; this study will focus on the feasibility and effectiveness of plasma therapy.

Another possible treatment option is monoclonal antibody therapy. Bevacizumab, a humanized monoclonal antibody, blocks vascular endothelial growth factor (VEGF) to halt the angiogenesis in cancer patients (Ellis, 2006 Pulmotect, Inc.

Note: †1, †2, and †3 are different arms of parallel intervention.

As COVID-19 spreads rapidly, the shortest and fastest approaches such as drug repurposing could be of the right choice that needs to be employed to discover potential therapeutics. Currently, some repurposed drugs have shown therapeutic promise, and thus Favipiravir, for instance, has already received temporary approval for use in COVID-19 patients. Other compounds with antiviral potential, for example, β-d-N 4 -hydroxycytidine showing inhibitory effects against Chikungunya Virus, also need to be evaluated against SARS-CoV-2.

However, recent hype on hydroxychloroquine or chloroquine, for example, as COVID-19 therapy should be handled carefully, as some studies claimed unprecedented side-effects posed by these anti-malarial drugs (Mehra et al., 2020) . Simultaneously, the path to vaccine development also needs to be minimized for long-term protection, of course addressing all the possible side-effects. As viruses are prone to frequent mutation, vaccines based on a single target might not work for a longer time. Recently, in silico studies identified several protein subunits as vaccine candidates, combining them into a single vaccine or multiple epitope vaccines might give better results against SARS-CoV-2.

In this review, we revisited the current knowledge on the potential drug targets of therapeutic promise against SARS-CoV-2 infection and highlighted the application of the drug repurposing approach. The possible therapeutic options that are currently under clinical and preclinical studies have been discussed. We also compiled the current clinical trials mostly based on repurposing the therapeutic agents formerly designed for other indications that have been rapidly started during the early phase of the pandemic and are currently undergoing.

Although far from practical application, significant progress has been made in vaccine development. Overall, this current effort leaves some valuable information on prospective druggable targets and current options of possible therapeutic as well as preventive strategies, providing a comprehensive and systematic guideline for those who are dedicated to COVID-19 research.

Beyond the approaches that have been addressed in this review, the strategies aimed at priming the host immune responses are of great potential as individuals with a compromised immune system are particularly vulnerable to COVID-19. Moreover, along with viral-specific therapeutics, immunomodulatory and anti-inflammatory agents acting against nonspecific inflammatory responses also need to be focused. The lessons learned from this emerging pandemic can help us prepare in advance for any possible future epidemics. As we live in the era of big data, systematic and multidisciplinary approaches need to be employed to find drug targets and repurposing drugs for instant drug discovery. 

Natural killer cells: Development, maturation, and clinical utilization

Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses

SARS-CoV-2 vaccines: Status report

The proximal origin of SARS-CoV-2

Global patterns in coronavirus diversity

Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks

The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

Remdesivir for the treatment of Covid-19-Preliminary report

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Important role for the transmembrane domain of severe acute respiratory syndrome coronavirus spike protein during entry

Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues

Molecular dynamics simulations indicate the COVID-19 Mpro is not a viable target for small-molecule inhibitors design. bio-Rxiv

Experimental treatment with Favipiravir for COVID-19: An open-label control study

A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19

The convalescent sera option for containing COVID-19

Treatment with Lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset

Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice

Advances in the research of cytokine storm mechanism induced by Corona virus disease 2019 and the corresponding immunotherapies

Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. medRxiv 2020

Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection

Convalescent plasma as a potential therapy for COVID-19

The SARS-CoV-2 vaccine pipeline: An overview

Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Will children reveal their secret? The Coronavirus Dilemma

The utility of target-based discovery

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

Structure(s), function (s), and inhibition of the RNA-dependent RNA polymerase of noroviruses

Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus

Off-label use of Tocilizumab in patients with SARS-CoV-2 infection

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020

Autophagy and viruses: Adversaries or allies

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro

The spike protein of SARS-CoV-A target for vaccine and therapeutic development

The discovery of first-in-class drugs: Origins and evolution

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer

Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase

Coronaviruses: An overview of their replication and pathogenesis

Seasonal influenza vaccines

Phylogenetic network analysis of SARS-CoV-2 genomes

Development and implementation of papillomavirus prophylactic vaccines

SARS coronavirus and innate immunity

Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling

Understanding SARS-CoV-2-mediated inflammatory responses: From mechanisms to potential therapeutic tools

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Molecular definitions of autophagy and related processes

Effects of a SARS-associated coronavirus vaccine in monkeys

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-coronavirus infection

Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Severe acute respiratory syndrome-related coronavirus: The species and its viruses-A statement of the Coronavirus Study Group

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

A SARS-CoV-2-human proteinprotein interaction map reveals drug targets and potential drugrepurposing. bioRxiv

SARS coronavirus replicase proteins in pathogenesis. Virus Research

Development and characterization of a severe acute respiratory syndromeassociated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv 2020

Therapeutic cancer vaccines: Past, present, and future. Advances in Cancer Research

Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Zika viral proteome analysis reveals an epitope cluster within NS3 helicase as a potential vaccine candidate: an in silico study

Coronavirus puts drug repurposing on the fast track

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

SARS-associated coronavirus

Multi-Epitope Cluster Ep85B within the Mycobacterial Protein Ag85B Elicits Cell-Mediated and Humoral Responses in Mice

Development of SARS vaccines and therapeutics is still needed

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro

From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

In silico predicted mycobacterial epitope elicits in vitro T-cell responses

SARS coronavirus E protein in phospholipid bilayers: An x-ray study

The architecture of SARS-CoV-2 transcriptome. bioRxiv 2020

Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein

Exceptional flexibility in the sequence requirements for coronavirus small envelope protein function

Sarah Gilbert: Carving a path towards a COVID-19 vaccine

Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. bio-Rxiv

Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features

Development by self-digestion: Molecular mechanisms and biological functions of autophagy

Receptor recognition mechanisms of coronaviruses: A decade of structural studies

Structure, function, and evolution of coronavirus spike proteins

Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

Varicella zoster virus vaccines: effective, but concerns linger

Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: The application of Lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR

The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis

The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase

A review of the anti-inflammatory effects of Rosmarinic acid on inflammatory diseases

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020

The genome sequence of the SARS-associated coronavirus

The molecular biology of coronaviruses

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV

The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome

SARS-CoV-2 and COVID-19 in older adults: What we may expect regarding pathogenesis, immune responses, and outcomes

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

SARS-CoV-2: A storm is raging

Arabinoxylan rice bran (MGN-3/biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma in vitro and in vivo

Structure and inhibition of the SARS coronavirus envelope protein ion channel

An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy

Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzyme

Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs

Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis

Review of siltuximab in the treatment of multicentric Castleman's disease

Effects of chloroquine on viral infections: An old drug against today's diseases?

A complex zinc finger controls the enzymatic activities of nidovirus helicases

Immunoinformatics aided prediction of cytotoxic T cell epitope of respiratory syncytial virus

On the use of corticosteroids for 2019-nCoV pneumonia

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

A Transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase

Discovery and synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses

Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry

The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles

Continuous and discontinuous RNA synthesis in coronaviruses

RNA-dependent RNA polymerase: Addressing Zika outbreak by a phylogeny-based drug target study

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

The intracellular sites of early replication and budding of SARS-coronavirus

SARS-CoV ORF1b-encoded nonstructural proteins 12-16: Replicative enzymes as antiviral targets

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine

Mechanisms of action of ribavirin in antiviral therapies

Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs

The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5 0 to 3 0 viral helicases

Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by Remdesivir

Convalescent plasma: A possible treatment of COVID-19 in India

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Into the eye of the cytokine storm

Structural basis for human coronavirus attachment to sialic acid receptors

Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins

The RNA-dependent-RNA polymerase, an emerging antiviral drug target for the Hendra virus

RNA dependent RNA polymerases: Insights from structure, function and evolution

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Efficacy and safety of arbidol in treatment of naturally acquired influenza

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

Remdesivir in adults with severe COVID-19: A randomised, doubleblind, placebo-controlled, multicentre trial

SARS coronavirus E protein forms cation-selective ion channels

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Targeting the Endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19

In vitro antiviral activity and projection of optimized dosing Design of Hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target

Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak

Phenotypic screens as a renewed approach for drug discovery

Aberrant pathogenic GM-CSF T cells and inflammatory CD14 monocytes in severe pulmonary syndrome patients of a new coronavirus

Broad-spectrum antiviral agents

Coronaviruses -drug discovery and therapeutic options

Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review